COMPOUND

Compounds / Bioregulators

Bronchogen

Bronchogen (Ala-Glu-Asp-Leu / AEDL Tetrapeptide)

Bioregulators SubQ · Oral Not FDA approved

Khavinson family bioregulator developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Synthetic tetrapeptide developed for bronchial epithelium modulation, used in Russia as adjunct in chronic bronchitis and COPD. Most efficacy data is from one Russian lab; independent Western replication is essentially absent. Sequence is AEDL: vendor and Russian academic consensus; some legacy reference docs truncate it as 'AED'.

At a glance

Routes
SubQ · Oral
Vial sizes
20 mg
Evidence base
2 studies 2 preclinical

Mechanism

Per the Khavinson 'short-peptide bioregulator' hypothesis, AEDL is proposed to bind DNA in the major groove at guanine N7 sites, modulating gene expression in bronchial epithelial cells. Mechanism is contested in mainstream pharmacology because tetrapeptides are normally degraded in serum within minutes. Reported preclinical effects: increased secretory IgA in BALF and regeneration markers in animal models; modulation of bronchial epithelial differentiation markers, anti-inflammatory effects (decreased COX-2, TNF-α), restoration of mucociliary clearance markers in animal models.

Dosing

No standardized human dosing has been established. Every catalogued study for Bronchogen is preclinical or a literature review. Amounts used in animal models do not translate directly to humans.

Published evidence

  1. Animal in vivo 2015

    Peptide AEDL and bronchopulmonary tissue regeneration

    Khavinson VK, Tarnovskaya SI, et al. Bull Exp Biol Med

    AEDL increased bronchial sIgA in BALF and supported regeneration markers in animal models.

  2. In vitro 2014

    Peptide AEDL effects on bronchial epithelial cell gene expression and DNA binding

    Khavinson VK, Tendler SM, et al. Bull Exp Biol Med

    AEDL bound DNA in the major groove at guanine N7 site; modulated bronchial epithelial differentiation and inflammatory gene expression in vitro.

Reported side effects

Long-term safety unverified outside Russia
Unknown Mild · Khavinson group reports a clean AE profile; no Western replication.

Interactions

  • Chonluten Synergy

    Both Khavinson respiratory peptides: Bronchogen targets bronchial epithelium, Chonluten targets bronchial mucosa/alveoli.

Reconstitution and storage

20 mg vial; 2-5 mL BAC water. At 4 mg/mL, 100 mcg = 0.025 mL.

Lyophilized: room temp short-term, refrigerate for >30 days. Reconstituted: refrigerate, use within 30 days.

Open the reconstitution calculator for Bronchogen